Support our Foundation of Myology project
mRNA vaccines in MNM: a satisfactory response despite muscle atrophy
Partager sur
An American team studied the impact of muscle atrophy and corticosteroid therapy on the immune response to messenger RNAmacromolécule constituée d’une seule chaîne de nucléotides (simple brin) résultant de la transcription (copie) de l’ADN. (mRNA) vaccines against SARS-CoV-2 in 14 people aged between 20 and 60 with neuromuscular diseases (MNM). Participants were mostly nonambulant (13/14) and had Duchenne or Becker muscular dystrophy (9/14), SMN1-related proximal spinal muscular atrophy (SMA) (1/14) or limb girdle muscular dystrophy (2/14).
The results of this study show that:
- IgG levels 14 days after the second injection of the vaccine are comparable in people with vaccinated MNM and in a control group without MNM also vaccinated;
- compared to an unvaccinated control group having contracted Covid-19 (Covid+), IgG levels are 11 times higher for vaccinated people (healthy or suffering from MNM but not treated with corticosteroids) and nine times for patients vaccinated and on corticosteroids;
- all vaccinated people perform better in the virusCe sont les plus petits micro-organismes vivants. Pour vivre et se multiplier, ils parasitent des cellules dont ils détournent à leur profit la machinerie. neutralization test (+52.9%) than Covid+ people;
- post-vaccination symptoms remain moderate and comparable between participants with and without MNM.
These results suggest a correct vaccine response and protection rate, in the short term, in patients affected by MNM.